Very important paper showing high sensitivity to anti-PD1 single agent in patients with >90% PDL1 NSCLC. Need for an additional biomarker (TMB ? CD8 ?) to reach outlier sensitivity, and withhold chemo. work in progress. tks @DrMarkAwad for having chosen Annals to publish it ! Tweet added by FabriceAndre @FAndreMD

FabriceAndre

5 years

Very important paper showing high sensitivity to anti-PD1 single agent in patients with >90% PDL1 NSCLC. Need for an additional biomarker (TMB ? CD8 ?) to reach outlier sensitivity, and withhold chemo. work in progress. tks @DrMarkAwad for having chosen Annals to publish it !

Mark Awad

@DrMarkAwad

5 years

How do patients with NSCLC & very high PD-L1 levels ≥90% do with 1st-line pembrolizumab? Multi-institutional collaboration led by outstanding Elizabeth Jimenez Aguilar & Biagio Ricciuti now online @Annals_Oncology @BiagioMD @Elizabethjimag @DanaFarber

103

Replies

Umut. Dişel

@UmutDisel

5 years

@FAndreMD @DrMarkAwad Answer isn’t simple but, think simple- No one biomarker work sole, TMB CD8 And HRD state and absence of negative predictors (STK11- betaCatenin-B2M)